Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. [electronic resource]
Producer: 20130322Description: 143-9 p. digitalISSN:- 1527-9995
- Aged
- Anemia -- chemically induced
- Antineoplastic Agents -- adverse effects
- Carcinoma, Renal Cell -- drug therapy
- Disease Progression
- Dyspnea -- chemically induced
- Everolimus
- Fatigue -- chemically induced
- Female
- Humans
- Hyperglycemia -- chemically induced
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Pneumonia -- chemically induced
- Sirolimus -- adverse effects
- Stomatitis -- chemically induced
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.